Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism and how danger they drugs be
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tyrosine kinase Inhibitors (Imatinib & Nilotinib) | Drug | these drugs used in CML only |
| Measure | Description | Time Frame |
|---|---|---|
| Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors | Assessment of change in HbA1c levels in CML patients treated with TKIs. | Baseline and 3, 6, 9, and 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors | Assessment of changes in lipid profile including total cholesterol, triglycerides, LDL, and HDL in CML patients treated with TKIs. | Baseline and 3, 6, 9, and 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
CML patients
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nancy Atef Abdou, doctor | Contact | 01027607363 | 01153253658 | nancyatef918@gamil.com |
| mai mostafa kamal, prof | Contact |
| Name | Affiliation | Role |
|---|---|---|
| Mona mohamed soliman, prof | Assiut University | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35983065 | Background | Hwang SM, Im SH, Rudra D. Signaling networks controlling ID and E protein activity in T cell differentiation and function. Front Immunol. 2022 Aug 2;13:964581. doi: 10.3389/fimmu.2022.964581. eCollection 2022. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000092004 | Tyrosine Kinase Inhibitors |
| D000068877 | Imatinib Mesylate |
| C498826 | nilotinib |
| ID | Term |
|---|---|
| D047428 | Protein Kinase Inhibitors |
| D004791 | Enzyme Inhibitors |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009196 |
| Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D020164 | Chemical Actions and Uses |
| D001549 | Benzamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001565 | Benzoates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011743 | Pyrimidines |